ValiGen N.V., the European-American biotechnology company, today announced the restructuring of its management team, focusing its operational activities in Europe.

ValiGen is pleased to announce the appointment of Jeremy Curnock-Cook as acting Chief Executive Officer of ValiGen. He has been part of the ValiGen's board of directors for over two years. He was formerly the head of Rothschild's Bioscience unit where he established a most distinguished track record as biotechnology venture fund manager. As executive chairman of Bioscience Managers Ltd, he currently holds several positions as Director of biotechnology companies around the world. He brings 30 years of operating and management experience in the life science industry and a unique understanding of the investment community.

In this restructuring, Jeremy Curnock-Cook will rely on a management team led by Dr. Cecile Tharaud who has been promoted to the position of Chief Operating Officer of ValiGen NV, along with her continuing responsibilities as CEO of ValiGen SA, and Dr. Herbert Schuster who has been promoted to the position of Chief Medical Officer of ValiGen, in which capacity he is charged with providing medical and disease based oversight on all ValiGen's programs, along with his continuing responsibilities as CEO of InfoGen. This team also includes Dr. David Bradfute who has been promoted to the position of Vice President, Legal Affairs & Intellectual Property, and Philippe Rousseau who has been promoted to Director of Administration & Finance. These management changes follow the recent departures of Douglas Watson, formerly Chief Executive Officer, and Dr. Bernard Bihain, formerly Chief Scientific Officer of ValiGen. These individuals have left the company to pursue other interests.

"The Board of ValiGen is very pleased by the recent scientific advances we have seen in ValiGen's cholesterol and genoplasty programs", said Stephen Evans-Freke, Executive Chairman of ValiGen. "We are in the process of a major restructuring of ValiGen, the details of which we will announce shortly. The new ValiGen will have a leaner organization more tightly focused on its core programs, and a new European-based management team committed to building and realizing substantive shareholder value."